scholarly journals Correction: Jang, S.-E.; et al. Lactobacillus rhamnosus HN001 and Lactobacillus acidophilus La-14 Attenuate Gardnerella vaginalis-Infected Bacterial Vaginosis in Mice. Nutrients 2017, 9, 531

Nutrients ◽  
2017 ◽  
Vol 9 (7) ◽  
pp. 715
Author(s):  
Se-Eun Jang ◽  
Jin-Ju Jeong ◽  
Su-Young Choi ◽  
Hyunji Kim ◽  
Myung Han ◽  
...  
Nutrients ◽  
2017 ◽  
Vol 9 (6) ◽  
pp. 531 ◽  
Author(s):  
Se-Eun Jang ◽  
Jin-Ju Jeong ◽  
Su-Young Choi ◽  
Hyunji Kim ◽  
Myung Han ◽  
...  

2005 ◽  
Vol 13 (1) ◽  
pp. 25-30 ◽  
Author(s):  
Estelle Devillard ◽  
Jeremy P. Burton ◽  
Gregor Reid

Objective:Gardnerella vaginalishas long been the most common pathogen associated with bacterial vaginosis (BV). We aimed to test our hypothesis that symptoms and signs of BV do not necessarily indicate colonization by this organism, and often will not respond to standard metronidazole or clindamycin treatment.Methods:Using a relatively new molecular tool, PCR denaturing gradient gel electrophoresis (DGGE), the vaginal microflora of a woman with recalcitrant signs and symptoms of BV was investigated over a 6-week timeframe.Results:The vagina was colonized by pathogenic enterobacteriaceae, staphylococci andCandida albicans. The detection of the yeast by PCR-DGGE is particularly novel and enhances the ability of this tool to examine the true nature of the vaginal microflora. The patient had not responded to antifungal treatment, antibiotic therapy targeted at anaerobic Gram-negative pathogens such asGardnerella, nor daily oral probiotic intake ofLactobacillus rhamnosusGG. The failure to find the GG strain in the vagina indicated it did not reach the site, and the low counts of lactobacilli demonstrated that therapy with this probiotic did not appear to influence the vaginal flora.Conclusions:BV is not well understood in terms of its causative organisms, and further studies appear warranted using non-culture, molecular methods. Only when the identities of infecting organisms are confirmed can effective therapy be devized. Such therapy may include the use of probiotic lactobacilli, but only using strains which confer a benefit on the vagina of pre- and postmenopausal women.


1998 ◽  
Vol 42 (6) ◽  
pp. 1428-1432 ◽  
Author(s):  
F. Muli ◽  
J. K. Struthers

ABSTRACT Gardnerella vaginalis and Lactobacillus acidophilus have been shown to grow to high titers in a simple biofilm system. This system was used in the present investigation to compare the biofilm-eradicating concentrations (BECs) of amoxicillin, clindamycin, erythromycin, and metronidazole to standard tube MIC and minimum bactericidal concentration (MBC) results. With the lactobacillus, the BEC/tube MBC ratio was at least 16:1, while forG. vaginalis the ratio varied from 2:1 to 512:1. The simple continuous-culture system used in the present investigation is ideal for investigating the BEC for bacteria involved in complex ecological situations such as bacterial vaginosis and may be useful for the identification of the most effective and selective antibiotic therapy.


2016 ◽  
Vol 4 (5) ◽  
Author(s):  
Lloyd S. Robinson ◽  
Justin Perry ◽  
Sai Lek ◽  
Aye Wollam ◽  
Erica Sodergren ◽  
...  

Gardnerella vaginalis is a predominant species in bacterial vaginosis, a dysbiosis of the vagina that is associated with adverse health outcomes, including preterm birth. Here, we present the draft genome sequences of 15 Gardnerella vaginalis strains (now available through BEI Resources) isolated from women with and without bacterial vaginosis.


2021 ◽  
Vol 20 (3) ◽  
pp. 134-145
Author(s):  
N.B. Lazareva ◽  
◽  
E.V. Rebrova ◽  
A.Yu. Ryazanova ◽  
E.V. Shikh ◽  
...  

Metronidazole and clindamycin have been the main medications for the treatment of bacterial vaginosis (BV) for 60 years. Despite the available arsenal of therapeutic agents, the frequency of disease recurrence remains high, and therefore the search for new therapeutic approaches remains relevant. In 2017, the FDA (Food and Drug Administration, USA) approved the use of secnidazole for the treatment of BV. As a member of the 5-nitroimidazole group, secnidazole differs structurally from metronidazole and tinidazole by radical groups attached to the annular nitrogen next to the nitro group. Structural differences may explain physicochemical and biochemical differences (e.g., tissue distribution, metabolic pathways) between these agents within the same pharmacological class of 5-nitroimidazoles. Secnidazole has the longest half-life compared to other medications in this group, which can significantly increase adherence to treatment, due to the possibility of achieving a clinical effect after a single use and a low incidence of adverse drug reactions, comparable to placebo. Key words: bacterial vaginosis, gardnerella vaginalis, lactobacilli, metronidazole, secnidazole


Sign in / Sign up

Export Citation Format

Share Document